G to C transition at position -173 of MIF gene of the recipient is associated with reduced relapse rates after allogeneic stem cell transplantation.
暂无分享,去创建一个
E. Holler | R. Andreesen | H. Greinix | G. Jackson | A. Dickinson | D. Wolff | G. Hildebrandt | Yayi Chang | G. Jackson
[1] N. Song,et al. The association between MIF‐173 G>C polymorphism and prostate cancer in southern Chinese , 2009, Journal of surgical oncology.
[2] M. Asaka,et al. Serum macrophage migration inhibitory factor (MIF) levels after allogeneic hematopoietic stem cell transplantation , 2009, International journal of laboratory hematology.
[3] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[4] D. Hanauer,et al. CCR1/CCL5 (RANTES) receptor-ligand interactions modulate allogeneic T-cell responses and graft-versus-host disease following stem-cell transplantation. , 2007, Blood.
[5] Annette Lee,et al. Macrophage migration inhibitory factor (MIF) gene polymorphisms are associated with increased prostate cancer incidence , 2007, Genes and Immunity.
[6] A. Berrebi,et al. IL-8 secreted in a macrophage migration-inhibitory factor- and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival , 2007, Proceedings of the National Academy of Sciences.
[7] G. Kuchel,et al. Null mutation for Macrophage Migration Inhibitory Factor (MIF) is associated with less aggressive bladder cancer in mice , 2007, BMC Cancer.
[8] M. Sykes,et al. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. , 2007, Blood.
[9] Carlos Flores,et al. Macrophage migration inhibitory factor in acute lung injury: expression, biomarker, and associations. , 2007, Translational research : the journal of laboratory and clinical medicine.
[10] S. Brand,et al. Macrophage migration inhibitory factor (MIF) −173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease , 2007, Inflammatory bowel diseases.
[11] K. Iczkowski,et al. Inhibition of Macrophage Migration Inhibitory Factor or Its Receptor (CD74) Attenuates Growth and Invasion of DU-145 Prostate Cancer Cells1 , 2006, The Journal of Immunology.
[12] M. Imamura,et al. Effect of macrophage migration inhibitory factor (MIF) on acute graft-versus-host disease in a murine model of allogeneic stem cell transplantation. , 2006, Transplant Immunology.
[13] M. Asaka,et al. Regulation of Toll-like receptor 4 expression in mouse colon by macrophage migration inhibitory factor , 2006, Histochemistry and Cell Biology.
[14] R. Bucala,et al. Macrophage migration inhibitory factor. , 2005, Critical care medicine.
[15] R. Korngold,et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses , 2005, Nature Medicine.
[16] G. Fingerle-Rowson,et al. MIF loss impairs Myc-induced lymphomagenesis , 2005, Cell Death and Differentiation.
[17] T. Hagemann,et al. Macrophages Induce Invasiveness of Epithelial Cancer Cells Via NF-κB and JNK1 , 2005, The Journal of Immunology.
[18] Yuji Sato,et al. Evidence of dual function of macrophage migration inhibitory factor relevant to tumor progression and regression. , 2005, International Journal of Molecular Medicine.
[19] D. Jain,et al. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. , 2004, Blood.
[20] D. Ray,et al. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. , 2004, The Journal of endocrinology.
[21] G. Vogelsang,et al. Chronic graft versus host disease , 2004, British journal of haematology.
[22] C. Dinarello,et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[23] J. Epplen,et al. Complex genetic predisposition in adult and juvenile rheumatoid arthritis , 2004, BMC Genetics.
[24] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[25] C. Miracco,et al. Expression of macrophage migration inhibitory factor in diffuse systemic sclerosis , 2003, Annals of the rheumatic diseases.
[26] R. Bucala,et al. Macrophage migration inhibitory factor: an emerging therapeutic target in rheumatoid arthritis. , 2003, Arthritis and rheumatism.
[27] M. Suematsu,et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction , 2003, Nature Immunology.
[28] J. Crawford,et al. T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.
[29] E. Zeggini,et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. , 2002, Arthritis and rheumatism.
[30] R. Liang,et al. Macrophage migratory inhibitory factor (MIF) expression in acute graft-versus-host disease (GVHD) in allogeneic hemopoietic stem cell transplant recipients , 2002, Bone Marrow Transplantation.
[31] W. Thomson,et al. Macrophage migration inhibitory factor gene polymorphism is associated with sarcoidosis in biopsy proven erythema nodosum. , 2002, The Journal of rheumatology.
[32] N. Horiike,et al. Macrophage migration inhibitory factor activates antigen‐presenting dendritic cells and induces inflammatory cytokines in ulcerative colitis , 2002, Clinical and experimental immunology.
[33] J. Ferrara,et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium , 2002, Nature Medicine.
[34] J. Bernhagen,et al. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. , 2002, Microbes and infection.
[35] A. Thomson,et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. , 2001, Blood.
[36] A. Dickinson,et al. Interferon-gamma and interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched sibling bone marrow transplantation. , 2001, Blood.
[37] W. Thomson,et al. A novel 5′‐flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic‐onset juvenile idiopathic arthritis , 2001 .
[38] M. V. D. van den Brink,et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. , 2001, Blood.
[39] Y. Aizawa,et al. Contribution of TNF-α and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation , 2000, Bone Marrow Transplantation.
[40] R. Bucala,et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.
[41] M. Shlomchik,et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.
[42] R. Bucala,et al. An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma , 1999, Molecular medicine.
[43] A. Satoskar,et al. Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis , 1999, The Journal of experimental medicine.
[44] G. Jackson,et al. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. , 1998, Blood.
[45] R. Bucala,et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.
[46] C. Kozak,et al. Localization of the human gene for macrophage migration inhibitory factor (MIF) to chromosome 22q11.2. , 1997, Genomics.
[47] R. Bucala,et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Bernhagen,et al. MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.
[49] J. Bernhagen,et al. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.
[50] K. Tracey,et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.
[51] Rachel L. Mistur,et al. Graft-Versus-Host Disease , 2016 .
[52] J. David,et al. Molecular cloning of a cDNA encoding a human macrophage migration inhibitory factor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[53] P. Neiman,et al. CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.
[54] J. David. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. , 1966, Proceedings of the National Academy of Sciences of the United States of America.
[55] B. Bloom,et al. Mechanism of a Reaction in Vitro Associated with Delayed-Type Hypersensitivity , 1966, Science.
[56] J. Loutit,et al. Treatment of Murine Leukaemia with X‐Rays and Homologous Bone Marrow: II , 1957, British journal of haematology.
[57] J. Loutit,et al. Treatment of Murine Leukaemia with X Rays and Homologous Bone Marrow , 1956, British medical journal.
[58] T. Tahara,et al. Functional promoter polymorphisms of the macrophage migration inhibitory factor gene in gastric carcinogenesis. , 2008, Oncology reports.